Multicentric reticulohistiocytosis is a rare systemic disease characterized by the presence of non-Langerhans cell histiocytic infiltrate in several organ systems. Because its clinical presentation so closely resembles autoimmune conditions such as rheumatoid arthritis, it is often overlooked as a diagnosis and, even when recognized, presents a challenge for treatment because of a lack of consensus regarding guidelines for management. We here review 6 cases of multicentric reticulohistiocytosis (MRH) from 2 institutions to identify clinical features, treatment, and outcomes of MRH.
We identified 6 patients with MRH and reviewed their medical records to assess demographic data, clinical presentations, laboratory findings, comorbid conditions, histopathologic features, and pharmacotherapies.
All 6 patients had definite MRH as established by skin biopsy. All our patients were middle-aged white women in whom skin involvement preceded arthritic symptoms. Hand and knee involvement was most common, seen in 5 and 4 patients, respectively. Erosions of the distal interphalangeal joints were the most common radiographic abnormality, seen in 3 patients. Diagnosis of MRH was usually delayed, and once identified, treatment and the outcomes of these treatments varied considerably. Approximately 50% of our patients had concomitant hypothyroidism and hyperlipidemia. None were subsequently diagnosed with malignancy.
Multicentric reticulohistiocytosis is a rare but often overlooked systemic disease that rheumatologists are liable to encounter in their clinical practice. The presence of cutaneous findings, erosive disease involving the distal interphalangeal joints, and comorbid diseases, such as hyperlipidemia and hypothyroidism, are features that should prompt practitioners to consider pursuing a biopsy of the affected tissue in order to confirm or refute the diagnosis of MRH. Bisphosphonates alone may not be able to control disease activity, and patients are likely to need immunosuppressive agents for better control.